Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alphabet Inc Class A (GOOGL) vs Novavax Inc (NVAX) Price & Performance

Alphabet Inc Class ATrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Alphabet Inc Class A vs Novavax Inc — how do they compare? Alphabet Inc Class A trades at $343.69 (market cap $4.20T), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Alphabet Inc Class A is far larger — about 3206.1× Novavax Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

GOOGLNVAX
Market Cap
$4.20T$1.31B
Sector
MediaHealth
52-Week High
$402.62$11.19
52-Week Low
$199.32$6.22
Enterprise Value
$4.09T$889.30M
Dividend Yield
0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alphabet Inc Class A

Alphabet (GOOGL) is trading at $343.80, down 3.84% amid broader tech sector rotation. Despite the recent decline, the company maintains strong fundamentals with 2025 revenue of $402.84B and net income of $132.17B, representing a 32.8% profit margin. Technical indicators show bearish momentum with the stock testing support near $341, while analyst consensus remains overwhelmingly bullish with an 85% buy rating and $426.28 price target. Recent quarterly earnings have consistently exceeded expectations, with Q2 2026 EPS of $9.11 beating estimates by 217%.

The outlook remains positive given Alphabet's dominant market position, AI leadership, and strong cash flow generation. Key risks include antitrust scrutiny and tech sector volatility. With the stock trading below consensus targets and showing robust earnings growth, current levels present a potential entry point for long-term investors seeking exposure to AI and digital advertising growth.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.

Read more on GOOGL

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX